Adverse events occurred in 69 ( 60 % ) of 116 patients in the rosuvastatin 10 mg group versus 79 ( 64 % ) of 123 patients in the rosuvastatin 40 mg group versus 63 ( 57 % ) of 110 patients in the atorvastatin 80 mg group ; renal events occurred in nine ( 78 % ) versus 12 ( 98 % ) versus five ( 45 % ) .